BiotechTube

AFQ056 + Placebo

Phase 2Terminated
1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Patient Diagnosed With OCD and Resistant to SSRI Treatment

Conditions

Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses

Trial Timeline

Nov 1, 2013 → Nov 1, 2014

NCT ID
NCT01813019

About AFQ056 + Placebo

AFQ056 + Placebo is a phase 2 stage product being developed by Novartis for Patient Diagnosed With OCD and Resistant to SSRI Treatment. The current trial status is terminated. This product is registered under clinical trial identifier NCT01813019. Target conditions include Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses.

What happened to similar drugs?

20 of 20 similar drugs in Patient Diagnosed With OCD and Resistant to SSRI Treatment were approved

Approved (20) Terminated (1) Active (0)
✅ATG-FAstellas PharmaApproved
✅Clopidogrel + TicagrelorAstraZenecaApproved
✅OlaparibAstraZenecaApproved
✅BenralizumabAstraZenecaApproved
✅GefitinibAstraZenecaApproved
✅Imipenem + ImipenemMerckApproved
✅Cyclosporine - cyclosporine microemulsionNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (11)

NCT IDPhaseStatus
NCT04771143Phase 1Withdrawn
NCT03242928Phase 2Completed
NCT02920892Phase 2Completed
NCT01813019Phase 2Terminated
NCT01491529Phase 2Completed
NCT01385592Phase 2Completed
NCT01357239Phase 2Completed
NCT01253629Phase 2Completed
NCT01019473Phase 2Terminated
NCT00888004Phase 2Completed
NCT00582673Phase 2Completed

Competing Products

20 competing products in Patient Diagnosed With OCD and Resistant to SSRI Treatment

See all competitors
ProductCompanyStageHype Score
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744 + rHuEPO + rHuEPO + R744 placebo + rHuEPO placeboChugai PharmaceuticalPhase 3
40
R744 + Epoetin betaChugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744 + R744Chugai PharmaceuticalPhase 3
40
R744Chugai PharmaceuticalPhase 3
40
PLX3397 + TemozolomideDaiichi SankyoPhase 1/2
32
FK949EAstellas PharmaPhase 1
29
roxadustatAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
ASP8825Astellas PharmaPhase 1
29
ASP015KAstellas PharmaPhase 1
29
ASP7991Astellas PharmaPhase 1
29
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
40
ATG-FAstellas PharmaApproved
43
CelecoxibAstellas PharmaPre-clinical
26
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
40
roxadustatAstellas PharmaPhase 3
40
FK949EAstellas PharmaPhase 1
29